AAAAAA

   
Results: 1-20 |
Results: 20
LACK OF EFFECT OF MIZOLASTINE ON THE SAFETY AND PHARMACOKINETICS OF DIGOXIN ADMINISTERED ORALLY IN REPEATED DOSES TO HEALTHY-VOLUNTEERS
Authors: CHAUFOUR S LECOZ F DENOLLE T DUBRUC C CIMAROSTI I DESCHAMPS C ULLIAC N DELHOTALLANDES B ROSENZWEIG P
Citation: S. Chaufour et al., LACK OF EFFECT OF MIZOLASTINE ON THE SAFETY AND PHARMACOKINETICS OF DIGOXIN ADMINISTERED ORALLY IN REPEATED DOSES TO HEALTHY-VOLUNTEERS, International journal of clinical pharmacology and therapeutics, 36(5), 1998, pp. 286-291
EFFECT OF BROMAZEPAM VERSUS PLACEBO ON INHIBITION AND WAITING CAPACITY IN YOUNG-WOMEN WITH TRAITS OF ANXIETY
Authors: SCHUCK S ALLAIN H GANDON JM PATAT A MILLET V LECOZ F
Citation: S. Schuck et al., EFFECT OF BROMAZEPAM VERSUS PLACEBO ON INHIBITION AND WAITING CAPACITY IN YOUNG-WOMEN WITH TRAITS OF ANXIETY, Fundamental and clinical pharmacology, 12(4), 1998, pp. 463-467
ABSOLUTE BIOAVAILABILITY AND ELECTROENCEPHALOGRAPHIC EFFECTS OF CONVENTIONAL AND EXTENDED-RELEASE FORMULATIONS OF VENLAFAXINE IN HEALTHY-SUBJECTS
Authors: PATAT A TROY S BURKE J TROCHERIE S DANJOU P LECOZ F ALLAIN H GANDON JA
Citation: A. Patat et al., ABSOLUTE BIOAVAILABILITY AND ELECTROENCEPHALOGRAPHIC EFFECTS OF CONVENTIONAL AND EXTENDED-RELEASE FORMULATIONS OF VENLAFAXINE IN HEALTHY-SUBJECTS, Journal of clinical pharmacology, 38(3), 1998, pp. 256-267
RILUZOLE SINGLE-DOSE PHARMACOKINETICS IN PATIENTS WITH IMPAIRED LIVER-FUNCTION
Authors: PATAT A KIRKESSELI S LEFEBVRE P CALIC F MONTAY G LECOZ F GANDON JM
Citation: A. Patat et al., RILUZOLE SINGLE-DOSE PHARMACOKINETICS IN PATIENTS WITH IMPAIRED LIVER-FUNCTION, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 64-64
ABSOLUTE BIOAVAILABILITY AND EEG EFFECTS OF CT AND ER VENLAFAXINE FORMULATION
Authors: PATAT A TROCHERIE S LECOZ F TROY S BURKE J DANJOU P ALLAIN H GANDON JM
Citation: A. Patat et al., ABSOLUTE BIOAVAILABILITY AND EEG EFFECTS OF CT AND ER VENLAFAXINE FORMULATION, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 62-62
PHARMACODYNAMICS AND PHARMACOKINETICS OF 2 DOSE REGIMENS OF BEFLOXATONE, A NEW REVERSIBLE AND SELECTIVE MONOAMINE-OXIDASE INHIBITOR, AT STEADY-STATE IN HEALTHY-VOLUNTEERS
Authors: PATAT A LECOZ F DUBRUC C GANDON JM DURRIEU G CIMAROSTI I JEZEQUEL S CURET O ZIELENIUK I ALLAIN H ROSENZWEIG P
Citation: A. Patat et al., PHARMACODYNAMICS AND PHARMACOKINETICS OF 2 DOSE REGIMENS OF BEFLOXATONE, A NEW REVERSIBLE AND SELECTIVE MONOAMINE-OXIDASE INHIBITOR, AT STEADY-STATE IN HEALTHY-VOLUNTEERS, Journal of clinical pharmacology, 36(3), 1996, pp. 216-229
RANDOMIZED DOUBLE-BLIND-STUDY OF MINAPRIN E VERSUS PLACEBO ON MEMORY LOSS
Authors: ALLAIN H BELLIARD S LIEURY A MENARD G PATAT A LECOZ F GANDON JM
Citation: H. Allain et al., RANDOMIZED DOUBLE-BLIND-STUDY OF MINAPRIN E VERSUS PLACEBO ON MEMORY LOSS, Therapie, 51(2), 1996, pp. 155-162
SYSTEMIC AND REGIONAL HEMODYNAMIC AND BIOLOGICAL EFFECTS OF A NEW KAPPA-OPIOID AGONIST, NIRAVOLINE, IN HEALTHY-VOLUNTEERS
Authors: BELLISSANT E DENOLLE T SINNASSAMY P BICHET DG GIUDICELLI JF LECOZ F GANDON JM ALLAIN H
Citation: E. Bellissant et al., SYSTEMIC AND REGIONAL HEMODYNAMIC AND BIOLOGICAL EFFECTS OF A NEW KAPPA-OPIOID AGONIST, NIRAVOLINE, IN HEALTHY-VOLUNTEERS, The Journal of pharmacology and experimental therapeutics, 278(1), 1996, pp. 232-242
DETERMINATION OF THE MAXIMAL TOLERATED DOSE OF A NEW ACUTE ORAL CAFFEINE FORMULATION IN HEALTHY-VOLUNTEERS
Authors: GANDON JM LECOZ F ENSLEN M CHAUFFARD F TACHON P ALLAIN H PATAT A
Citation: Jm. Gandon et al., DETERMINATION OF THE MAXIMAL TOLERATED DOSE OF A NEW ACUTE ORAL CAFFEINE FORMULATION IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 81-81
COMPARATIVE-STUDY OF THE EFFECTS OF ZOPICLONE (7.5 MG), ZOLPIDEM, FLUNITRAZEPAM AND A PLACEBO ON NOCTURNAL COGNITIVE PERFORMANCE IN HEALTHY-SUBJECTS, IN RELATION TO PHARMACOKINETICS
Authors: ALLAIN H PATAT A LIEURY A LECOZ F JANUS C MENARD G GANDON JM
Citation: H. Allain et al., COMPARATIVE-STUDY OF THE EFFECTS OF ZOPICLONE (7.5 MG), ZOLPIDEM, FLUNITRAZEPAM AND A PLACEBO ON NOCTURNAL COGNITIVE PERFORMANCE IN HEALTHY-SUBJECTS, IN RELATION TO PHARMACOKINETICS, European psychiatry, 10, 1995, pp. 129-135
EFFECTS OF SINGLE AND MULTIPLE DOSES OF A NEW REVERSIBLE MAO-A INHIBITOR, BEFLOXATONE, ON PSYCHOMOTOR PERFORMANCE AND MEMORY IN HEALTHY-SUBJECTS
Authors: PATAT A GANDON JM DURRIEU G LECOZ F CURET O CIMAROSTI I ALLAIN H
Citation: A. Patat et al., EFFECTS OF SINGLE AND MULTIPLE DOSES OF A NEW REVERSIBLE MAO-A INHIBITOR, BEFLOXATONE, ON PSYCHOMOTOR PERFORMANCE AND MEMORY IN HEALTHY-SUBJECTS, Human psychopharmacology, 10(2), 1995, pp. 111-125
PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF THE EFFECTS OF ORAL AND INTRAVENOUS ADMINISTRATIONS OF DOFETILIDE ON VENTRICULAR REPOLARIZATION
Authors: LECOZ F FUNCKBRENTANO C MORELL T GHADANFAR MM JAILLON P
Citation: F. Lecoz et al., PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF THE EFFECTS OF ORAL AND INTRAVENOUS ADMINISTRATIONS OF DOFETILIDE ON VENTRICULAR REPOLARIZATION, Clinical pharmacology and therapeutics, 57(5), 1995, pp. 533-542
PHARMACODYNAMICS OF A NEW KAPPA-OPIOID AGONIST, NIRAVOLINE, IN HEALTHY-VOLUNTEERS
Authors: BELLISSANT E DENOLLE T SINNASSAMY P LECOZ F GANDON JM
Citation: E. Bellissant et al., PHARMACODYNAMICS OF A NEW KAPPA-OPIOID AGONIST, NIRAVOLINE, IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 142-142
USE OF FREE DHPG PLASMA-LEVELS TO ASSESS EQUIPOTENCY OF 2 DOSAGE REGIMENS OF BEFLOXATONE, A REVERSIBLE MAO-A INHIBITOR
Authors: PATAT A LECOZ F GANDON JM BECK A DURRIEU G CURET O ALLAIN H
Citation: A. Patat et al., USE OF FREE DHPG PLASMA-LEVELS TO ASSESS EQUIPOTENCY OF 2 DOSAGE REGIMENS OF BEFLOXATONE, A REVERSIBLE MAO-A INHIBITOR, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 146-146
PK PD INTERACTION STUDIES OF LISURIDE WITH ERYTHROMYCIN AND FOOD IN HEALTHY-VOLUNTEERS/
Authors: GANDON JM LECOZ F KUHNE G HUMPEL M ALLAIN H
Citation: Jm. Gandon et al., PK PD INTERACTION STUDIES OF LISURIDE WITH ERYTHROMYCIN AND FOOD IN HEALTHY-VOLUNTEERS/, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 191-191
RELATIONSHIPS BETWEEN ACUTE AND CHRONIC BETA-BLOCKING EFFECTS OF BISOPROLOL IN HEALTHY-VOLUNTEERS - A PRACTICAL APPROACH TO PREDICT INTENSITY OF BETA-BLOCKADE
Authors: JAMIN P LECOZ F FUNCKBRENTANO C POIRIER JM JAILLON P
Citation: P. Jamin et al., RELATIONSHIPS BETWEEN ACUTE AND CHRONIC BETA-BLOCKING EFFECTS OF BISOPROLOL IN HEALTHY-VOLUNTEERS - A PRACTICAL APPROACH TO PREDICT INTENSITY OF BETA-BLOCKADE, Journal of cardiovascular pharmacology, 23(4), 1994, pp. 658-663
STATUS OF THE FABRICATION AND TEST OF THE PROTOTYPE LHC LATTICE QUADRUPOLE MAGNETS
Authors: RIFFLET JM GIOVANNONI P LECOZ F LYRAUD C PEROT J VEDRINE P SIEGEL N TORTSCHANOFF T
Citation: Jm. Rifflet et al., STATUS OF THE FABRICATION AND TEST OF THE PROTOTYPE LHC LATTICE QUADRUPOLE MAGNETS, IEEE transactions on magnetics, 30(4), 1994, pp. 2458-2461
MECHANICAL TESTS ON THE PROTOTYPE LHC LATTICE QUADRUPOLE
Authors: VEDRINE P RIFFLET JM PEROT J GALLET B LYRAUD C GIOVANNONI P LECOZ F SIEGEL N TORTSCHANOFF T
Citation: P. Vedrine et al., MECHANICAL TESTS ON THE PROTOTYPE LHC LATTICE QUADRUPOLE, IEEE transactions on magnetics, 30(4), 1994, pp. 2475-2478
EFFECT OF 2 DOSES OF GINKGO-BILOBA EXTRACT (EGB-761) ON THE DUAL-CODING TEST IN ELDERLY SUBJECTS
Authors: ALLAIN H RAOUL P LIEURY A LECOZ F GANDON JM DARBIGNY P
Citation: H. Allain et al., EFFECT OF 2 DOSES OF GINKGO-BILOBA EXTRACT (EGB-761) ON THE DUAL-CODING TEST IN ELDERLY SUBJECTS, Clinical therapeutics, 15(3), 1993, pp. 549-558
THE ELDERLY HEALTHY VOLUNTEER - A NECESSI TY
Authors: ALLAIN H LECOZ F BUREAU M
Citation: H. Allain et al., THE ELDERLY HEALTHY VOLUNTEER - A NECESSI TY, Therapie, 48(3), 1993, pp. 239-242
Risultati: 1-20 |